News
Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an ...
Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an elevated risk of cancer with tofacitinib, compared to TNF inhibitors (TNFi).1 ...
PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback